KBI Biopharma Inc.’s recently expanded Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory establishment license.   This important designation demonstrates compliance with current Good Manufacturing Practice (cGMP) standards for the production and release of drug substances for clients.   The license allows KBI to fully support clients in their next phases of growth and certifies KBI’s manufacturing capabilities in a cGMP environment.   “It’s...